Publications Archive - KalVista Pharmaceuticals

Showing 7 out of 7

Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On Demand Treatment for Hereditary Angiodema

Davie R, Edwards H, Evans D, Hodgson S, Stocks M, Smith A, Rushbrooke L, Pethen S, Roe M, Clark D, McEwan P, Hampton S

Journal of Medicinal Chemistry

Absorption, metabolism, and excretion of [14C]-sebetralstat (KVD900 following a single oral does in healthy male participants

Mutch P, Bashir M, Jung B, Yi P, Iverson M

Xenobiotica

Sebetralstat Effectiveness in the Treatment of Hereditary Angioedema Attacks Rated Mild or Moderate at Baseline in the Phase 2 Trial

Longhurst HJ, Smith MD, Yea CM, Audhya PK

ASCIA 2022

Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients With Hereditary Angioedema

Aygören-Pürsün E, Zanichelli A, Cohn DM, Audhya PK, Williams P, Yea CM, Smith MD

EAACI 2022

Agreement of Patient Global Impression of Change With Attack Resolution or Use of Rescue Medication in Patients With Hereditary Angioedema

Audhya P, Williams P, Yea C, Cohn D

AAAAI 2022

KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results

Maetzel A, Smith MD, Duckworth EJ, Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Francombe D, Feener EP, Yea CM

Journal of Allergy and Clinical Immunology

Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.

Duckworth EJ, Murugesan N, Li L, Rushbrooke LJ, Lee DK, De Donatis GM, Maetzel A, Yea CM, Hampton SL, Feener EP

Clinical & Experimental Allergy

About

Science

Pipeline

Careers

Contact